---
title: "Novartis’ neuromuscular drug del-desiran fails Phase 3 HARBOR trial in DM1"
id: "stat-news-6-stat-neuromuscular-drug-from-novartis-fails-in-key-study-adding-to-pressure-on"
canonical_url: "https://medichelpline.com/clinical-feed/stat-news-6-stat-neuromuscular-drug-from-novartis-fails-in-key-study-adding-to-pressure-on"
content_type: "clinical_feed_article"
specialty: "Neurology"
source_name: "STAT News"
source_url: "https://www.statnews.com/2026/09/08/novartis-del-desiran-myotonic-dystrophy-harbor-trial-failure-neuromuscular/?utm_campaign=rss"
published_at: "2026-09-08T07:28:55.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Novartis’ neuromuscular drug del-desiran fails Phase 3 HARBOR trial in DM1
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/stat-news-6-stat-neuromuscular-drug-from-novartis-fails-in-key-study-adding-to-pressure-on
- **Specialty:** [Neurology](https://medichelpline.com/clinical-feed/neurology.md)
- **Primary Source:** STAT News
- **Source URL:** [Original Journal Publication](https://www.statnews.com/2026/09/08/novartis-del-desiran-myotonic-dystrophy-harbor-trial-failure-neuromuscular/?utm_campaign=rss)
- **Published At:** 2026-09-08T07:28:55.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Novartis announced that its experimental neuromuscular agent **del-desiran** failed to meet the primary endpoint in the Phase 3 **HARBOR trial** for **myotonic dystrophy type 1 (DM1)**, a rare condition that causes progressive muscle stiffness and weakness. - The trial’s primary endpoint was improvement versus placebo in **video hand opening time (vHOT)**, a measure of the hand’s ability to relax after squeezing; del-desiran did not outperform placebo on this measure. - This setback is Novartis’ second major trial failure in days, following a separate pivotal cardiovascular trial loss reported earlier for a different therapy (pelacarsen), compounding pressure on the company. - The twin trial failures raise investor and industry concerns about Novartis’ pipeline strength and acquisition strategy as it faces a major patent cliff; the company did register a recent regulatory/clinical success with a multiple sclerosis drug the prior week. - The stock fell in early trading in Switzerland, dropping by as much as 10% according to the source. - The STAT article reporting the HARBOR result is behind the STAT+ paywall; additional trial details, such as full efficacy data, safety outcomes, enrollment, or next steps from Novartis, were not reported in the publicly available portion of the story. - The report was published Sept. 8, 2026, by Europe correspondent Andrew Joseph for STAT; contact and subscription details and related STAT coverage of Novartis’ other trial failure were linked in the article. - Source-only facts: the article notes both the HARBOR trial result and the contemporaneous cardiovascular trial failure, mentions the company’s recent MS win, and cites market reaction; it does not provide granular trial data or company strategic responses in the accessible text.
## Clinical Analysis & Structured Key Points
[Skip to Main Content](https://www.statnews.com/2026/09/08/novartis-del-desiran-myotonic-dystrophy-harbor-trial-failure-neuromuscular/?utm_campaign=rss#wrapper) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo-white.svg) ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) ](https://www.statnews.com/) * [Manage alerts for this article](https://www.statnews.com/my-account/edit/#emails) * Email this article * [Share this article](https://www.statnews.com/2026/09/08/novartis-del-desiran-myotonic-dystrophy-harbor-trial-failure-neuromuscular/?utm_campaign=rss) [cardiology](https://www.statnews.com/topic/cardiology/) [Novartis](https://www.statnews.com/topic/novartis/) [research](https://www.statnews.com/topic/research/) * [Newsletters](https://www.statnews.com/signup/) * [Log In](https://www.statnews.com/login/) * [My Account](https://www.statnews.com/my-account/) * [Subscribe Now](https://www.statnews.com/stat-plus/) My Account * [Settings Complete your personal information for a more tailored experience ](https://www.statnews.com/my-account/) * [Billing](https://www.statnews.com/my-account/billing/) * [Log In](https://www.statnews.com/login/) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) Reporting from the frontiers of health and medicine ](https://www.statnews.com/) * [Newsletters](https://www.statnews.com/signup/) * [Log In](https://www.statnews.com/login/) * [My Account](https://www.statnews.com/my-account/) * [Subscribe Now](https://www.statnews.com/stat-plus/) * [Biotech](https://www.statnews.com/category/biotech/) * [Pharma](https://www.statnews.com/category/pharma/) * [Public Health](https://www.statnews.com/category/health/) * [Health Tech](https://www.statnews.com/category/health-tech/) * [Policy](https://www.statnews.com/category/politics/) * [Science](https://www.statnews.com/category/in-the-lab/) * [First Opinion](https://www.statnews.com/category/first-opinion/) * [STAT+](https://www.statnews.com/topic/stat-plus/) * [STAT Events](https://www.statnews.com/events/) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) ](https://www.statnews.com/) Search * [Log In](https://www.statnews.com/login/) * [Subscribe Now](https://www.statnews.com/stat-plus/) * [My Account](https://www.statnews.com/my-account/) [Home](https://www.statnews.com/) News * [Latest](https://www.statnews.com/latest/) * [Series & Investigations](https://www.statnews.com/stat-series-and-investigations-award-winning-journalism/) * Business * [Biotech](https://www.statnews.com/category/biotech/) * [Pharma](https://www.statnews.com/category/pharma/) * [Health Tech](https://www.statnews.com/category/health-tech/) * [Health Insurance](https://www.statnews.com/category/insurance/) * [Hospitals](https://www.statnews.com/category/hospitals/) * [Medical Devices](https://www.statnews.com/topic/medical-devices/) * Washington * [Policy](https://www.statnews.com/category/politics/) * [FDA](https://www.statnews.com/topic/fda/) * [NIH](https://www.statnews.com/topic/nih/) * Science * [CRISPR](https://www.statnews.com/topic/crispr/) * [Gene Therapy](https://www.statnews.com/topic/gene-therapy/) * [Neuroscience](https://www.statnews.com/topic/neuroscience/) * Public Health * [Addiction](https://www.statnews.com/topic/addiction/) * [Covid-19](https://www.statnews.com/topic/coronavirus/) * [Abortion](https://www.statnews.com/topic/abortion/) * [Health Disparities](https://www.statnews.com/topic/health-disparities/) * [Infectious Disease](https://www.statnews.com/topic/infectious-disease/) * [Mental Health](https://www.statnews.com/topic/mental-health/) * Disease * [Cancer](https://www.statnews.com/topic/cancer/) * [Cardiovascular Disease](https://www.statnews.com/topic/cardiovascular-disease/) * [Chronic Disease](https://www.statnews.com/topic/chronic-disease/) * [Diabetes](https://www.statnews.com/topic/diabetes/) * [Alzheimer's](https://www.statnews.com/topic/alzheimers/) * [Obesity](https://www.statnews.com/topic/obesity/) * Features * [Health Care Costs](https://www.statnews.com/health-insurance-costs-out-of-pocket-out-of-reach-series/) * [The Deadliest Drug](https://www.statnews.com/alcohol-epidemic-hiding-plain-sight-deadliest-drug-series/) * [Science, Shattered](https://www.statnews.com/american-science-shattered/) [Newsletters](https://www.statnews.com/signup/) [Opinion](https://www.statnews.com/category/first-opinion/) Columns * [Adam Feuerstein](https://www.statnews.com/category/adams-take/) * [Matthew Herper](https://www.statnews.com/category/matts-take/) * [Ed Silverman](https://www.statnews.com/category/pharmalot-view/) [Reports](https://reports.statnews.com/) [E-books](https://www.statnews.com/ebooks/) [Podcasts](https://www.statnews.com/podcasts/) [Tools & Trackers](https://www.statnews.com/trackers/) * [CRISPR Tracker](https://www.statnews.com/feature/crispr/tracker/) * [Breakthrough Device Tracker](https://www.statnews.com/feature/stat-plus/breakthrough-device-designation-fda-tracker/) * [Generative AI Tracker](https://www.statnews.com/feature/stat-plus/generative-ai-health-hospitals-tracker/) * [Obesity Drug Tracker](https://www.statnews.com/2023/09/12/new-weight-loss-drug-tracker-novo-nordisk-eli-lilly/) [Events](https://www.statnews.com/events/) * [Upcoming Events](https://www.statnews.com/events#upcoming-events) * [Summits](https://www.statnews.com/stat-summits/) [Community](https://www.statnews.com/community/) * [STAT Wunderkinds 2026](https://www.statnews.com/wunderkinds-nominate/) [Video](https://youtube.com/@Statnews) [Advertise](https://www.statnews.com/advertise/) * [STAT Brand Studio](https://sbs.statnews.com/) What's the word? Test your knowledge with our new weekday mini crossword [ Start solving ](https://www.statnews.com/stat-mini-crossword/) [STAT Plus](https://www.statnews.com/stat-plus/)[Pharma](https://www.statnews.com/category/pharma/) # Neuromuscular drug from Novartis fails in key study, adding to pressure on company ## The miss in a condition known as DM1 follows a cardiovascular trial misfire * [Manage alerts for this article](https://www.statnews.com/my-account/edit/#emails) * Email this article * [Share this article](https://www.statnews.com/2026/09/08/novartis-del-desiran-myotonic-dystrophy-harbor-trial-failure-neuromuscular/?utm_campaign=rss) ![](https://www.statnews.com/wp-content/uploads/2018/10/STAT_Novartis01-645x645.jpg) Ruby Wallau for STAT ![](https://www.statnews.com/wp-content/uploads/2021/02/andrew-j-avatar-small-1-80x80.png) By [Andrew Joseph](https://www.statnews.com/staff/andrew-joseph/) Sept. 8, 2026 Europe Correspondent ![](https://www.statnews.com/wp-content/uploads/2021/02/andrew-j-avatar-small-1-80x80.png) [Andrew Joseph](https://www.statnews.com/staff/andrew-joseph/) 1. [](https://x.com/DrewQJoseph "X") andrew.joseph@statnews.com Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. An experimental drug for a rare neuromuscular condition failed to improve muscle function in a pivotal study, Novartis said Tuesday, the company’s [second major trial collapse](https://www.statnews.com/2026/09/04/novartis-therapy-pelacarsen-fails-cardiovascular-trial/) in a matter of days. The two study flops will likely stoke concerns about Novartis’ pipeline and its acquisition strategy as it navigates a major patent cliff, though the company did see a victory with a multiple sclerosis drug last week. The stock was down by as much as 10% in early trading in Switzerland. Advertisement The Phase 3 HARBOR trial was testing the drug del-desiran in a condition called myotonic dystrophy type 1, known as DM1, which causes progressive muscle stiffness and weakness. Novartis said the drug did not meet its primary endpoint of outperforming placebo on improving video hand opening time, or vHOT, a measure of the hand’s ability to relax after squeezing. STAT+ Exclusive Story Already have an account? [Log in](https://www.statnews.com/login/) ![STAT+](https://www.statnews.com/wp-content/themes/stat/images/stat-plus-breaker-bg.png) [ ![STAT+](https://www.statnews.com/wp-content/themes/stat/images/stat-plus-logo-white.svg) ](https://www.statnews.com/stat-plus/) ## This article is exclusive to STAT+ subscribers ### Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+. Already have an account? [Log in](https://www.statnews.com/login/) Individual plans Group plans Monthly $39 Totals $468 per year [$39/month](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-monthly-39-0) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-monthly-39-0) Totals $468 per year Starter $30 for 3 months, then $399/year [$30 for 3 months](https://www.statnews.com/stat-plus/subscribe/?plan=3mo30_yearly_pw) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=3mo30_yearly_pw) Then $399/year Annual $399 Save 15% [$399/year](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-annually-399-0) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-annually-399-0) Save 15% 11+ Users Custom Savings start at 25%! [Request A Quote](https://www.statnews.com/stat-plus/group-subscriptions/) [Request A Quote](https://www.statnews.com/stat-plus/group-subscriptions/) Savings start at 25%! 2-10 Users $300 Annually per user [$300/year](https://www.statnews.com/stat-plus/subscribe/?plan=stat_plus_groups_self_serve_0) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=stat_plus_groups_self_serve_0) $300 Annually per user [View All Plans](https://www.statnews.com/stat-plus/) [![STAT+](https://www.statnews.com/wp-content/themes/stat/images/stat-plus-logo.svg)](https://www.statnews.com/stat-plus/) To read the rest of this story subscribe to STAT+. [Subscribe](https://www.statnews.com/stat-plus/) [Log In](https://www.statnews.com/login/) [drug development](https://www.statnews.com/topic/drug-development/), [Pharmaceuticals](https://www.statnews.com/topic/pharmaceuticals/), [rare disease](https://www.statnews.com/topic/rare-disease/), [STAT+](https://www.statnews.com/topic/stat-plus/) [Submit a correction request](https://www.statnews.com/contact/?how_can_we_help_=Editorial%20Correction%20Request)[Reprints](https://www.parsintl.com/publications/stat/) 1. ![](https://www.statnews.com/wp-content/uploads/2021/02/andrew-j-avatar-small-1-80x80.png) [Andrew Joseph](https://www.statnews.com/staff/andrew-joseph/) 1. [](https://x.com/DrewQJoseph "X") 2. Europe Correspondent 1. [](https://x.com/DrewQJoseph "X") 2. Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. ![](https://www.statnews.com/wp-content/themes/stat/images/article-new/envelope-open.svg) ![](https://www.statnews.com/wp-content/uploads/2023/06/Morning-Rounds-Logo-Black-640x295.png) ### Newsletter Understand how science, health policy, and medicine shape the world every day Please enter a valid email address. Sign Up Your data will be processed in accordance with our [Privacy Policy](https://www.statnews.com/privacy/) and [Terms of Service](https://www.statnews.com/terms-conditions/). You may opt out of receiving STAT communications at any time. Advertisement Most Popular 1. ![](https://www.statnews.com/wp-content/uploads/2026/01/heart-1-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Novo Nordisk stops two cardiovascular trials of drug aimed at lowering inflammation](https://www.statnews.com/2026/09/07/novo-nordisk-heart-studies-inflammation-ziltivekimab/) 2. ![](https://www.statnews.com/wp-content/uploads/2018/10/STAT_Novartis02-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Novartis’ experimental cardiovascular drug fails a pivotal study](https://www.statnews.com/2026/09/04/novartis-therapy-pelacarsen-fails-cardiovascular-trial/) 3. ![](https://www.statnews.com/wp-content/uploads/2026/02/AdobeStock_330230890-80x80.jpeg) [AMA CEO: Deepfake doctors are a threat to public health](https://www.statnews.com/2026/02/17/deepfake-doctors-scam-ama/) 4. ![](https://www.statnews.com/wp-content/uploads/2026/08/AdobeStock_729644280_Editorial_Use_Only-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [FDA approves Protagonist and Takeda’s drug for rare blood cancer](https://www.statnews.com/2026/08/30/fda-approves-mimrylo-takeda-protagonist-treatment-for-polycythemia-vera/) 5. ![](https://www.statnews.com/wp-content/uploads/2025/12/NOVO_PILL_01-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [With the Wegovy pill, Novo Nordisk undercuts Eli Lilly in direct-to-consumer market](https://www.statnews.com/2025/12/29/wegovy-pill-price-novo-nordisk-strategy-weight-loss-drugs/) #### [ Reports ](https://reports.statnews.com/) [ ![](https://www.statnews.com/wp-content/uploads/2026/08/2026_CancerReport_ReportCover-328x424.jpg) Explore Cancer’s transformational moments: KRAS, CAR-T, immunotherapy, and more ](https://reports.statnews.com/products/cancer-transformational-moments-advances-in-kras-car-t-immunotherapy) Advertisement #### [Events](https://www.statnews.com/events/) [ ![](https://www.statnews.com/wp-content/uploads/2026/07/924_Samsung_VirtualEvent_Wordpress_FeaturedImage-80x80.jpg) Biosimilars: Have We Reached an Inflection Point? Virtual Sep 24 ](https://www.statnews.com/event/biosimilars-what-is-next-virtual-event-sept-2026/) [ ![](https://www.statnews.com/wp-content/uploads/2026/01/Flagship2026_Wordpress_CalendarImageRegGoLive-1-80x80.jpg) 2026 STAT Summit Boston, MA Oct 14 ](https://www.statnews.com/event/2026-stat-summit/) [ ![](https://www.statnews.com/wp-content/uploads/2026/07/2026_DD_OfficeHours_VirtualEvent_Wordpress_CalendarImage-80x80.jpg) Office Hours with Isabella Cueto and Lev Facher Virtual Jul 29 ](https://www.statnews.com/event/deadliest-drug-series-office-hours-ama-july-2026/) Most Read in [STAT+](https://www.statnews.com/stat-plus/) 1. ![](https://www.statnews.com/wp-content/uploads/2026/08/AdobeStock_1240429246-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [NIH proposal to cap research grants draws mixed reception, agency says](https://www.statnews.com/2026/09/01/nih-grant-cap-proposal-researcher-feedback/) 2. ![](https://www.statnews.com/wp-content/uploads/2026/09/Lindsay_Clancy_Trial_8_1_1-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Lindsay Clancy case exposes dangers of fragmented U.S. health system, experts say](https://www.statnews.com/2026/09/04/lindsay-clancy-health-care-silos-postpartum-care-failures/) 3. ![](https://www.statnews.com/wp-content/uploads/2018/10/STAT_Novartis02-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Novartis’ experimental cardiovascular drug fails a pivotal study](https://www.statnews.com/2026/09/04/novartis-therapy-pelacarsen-fails-cardiovascular-trial/) 4. ![](https://www.statnews.com/wp-content/uploads/2024/05/s3___bgmp-arc_arc-feeds_generic-photos_to-arc_Wiggs-_Bedford_2-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Ultragenyx drug to treat Angelman syndrome, a rare disease, fails late-stage trial](https://www.statnews.com/2026/09/02/ultragenyx-drug-angelman-syndrome-clinical-trial/) 5. ![](https://www.statnews.com/wp-content/uploads/2026/09/AP23227774736501-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Recipients of gene-edited pig kidneys successfully receive human organs](https://www.statnews.com/2026/09/03/recipients-of-gene-edited-pig-kidneys-receive-human-organs/) #### Recommended ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Health Health September 8, 2026 ### [ Reynolds is selling fruity new vapes unauthorized by FDA ](https://www.statnews.com/2026/09/08/fda-guidance-reynolds-selling-fruity-new-vapes-unauthorized/) By [Sarah Todd](https://www.statnews.com/staff/sarah-todd/) ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Health Health September 8, 2026 ### [ A breakthrough pancreatic cancer drug won approval. They still struggle to access it ](https://www.statnews.com/2026/09/08/pancreatic-cancer-patients-caught-beween-fda-drug-approval-insurance-coverage/) By [Angus Chen](https://www.statnews.com/staff/angus-chen/) Advertisement ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Exclusive Exclusive September 8, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: UnitedHealth executives shower high-ranking Democrat with donations ahead of midterms ](https://www.statnews.com/2026/09/08/uhg-political-donations-katherine-clark-democratic-whip-medicare-for-all/) By [Bob Herman](https://www.statnews.com/staff/bob-herman/) ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) First Opinion First Opinion September 8, 2026 ### [ It’s time to take the gloves off during vaccination ](https://www.statnews.com/2026/09/08/flu-vaccination-season-gloves-waste-climate-changes/) By Cassandra Thiel and Preeti Jaggi ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) First Opinion First Opinion September 8, 2026 ### [ I’m a fat medical student. I refuse to let myself be shamed for it ](https://www.statnews.com/2026/09/08/fat-medical-student-inclusivity-advocacy-health-at-any-size-physician/) By Jessica Rosenblum #### Subscriber Picks 1. ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Abivax has still not been acquired. What’s going on? ](https://www.statnews.com/2026/09/03/abivax-acquisition-target-replimune-fda/) By [Adam Feuerstein](https://www.statnews.com/staff/adam-feuerstein/) 2. ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Lindsay Clancy case exposes dangers of fragmented U.S. health system, experts say ](https://www.statnews.com/2026/09/04/lindsay-clancy-health-care-silos-postpartum-care-failures/) By [Tara Bannow](https://www.statnews.com/staff/tara-bannow/) 3. ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: ADA review of members’ expulsion denies group censored opinions, called in police ](https://www.statnews.com/2026/09/01/ada-members-review-june-expulsion-denies-censoring-opinions-calling-new-orleans-police/) By [Elizabeth Cooney](https://www.statnews.com/staff/elizabeth-cooney/) 4. ### [ Doctors groups release vaccination guidelines ahead of respiratory illness season ](https://www.statnews.com/2026/09/02/vaccine-integrity-project-fall-winter-guidelines-rsv-covid-flu-shots/) By [Helen Branswell](https://www.statnews.com/staff/helen-branswell/) 5. ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: The ERs that can turn patients away — and are reaping millions ](https://www.statnews.com/2026/06/29/nutex-health-micro-hospitals-er-loophole-idr-profits/) By [Tara Bannow](https://www.statnews.com/staff/tara-bannow/) Share options * [ X ](https://twitter.com/intent/tweet?url=https://www.statnews.com/2026/09/08/novartis-del-desiran-myotonic-dystrophy-harbor-trial-failure-neuromuscular/&via=statnews&text=Neur
## Related Clinical Research

- [Ultragenyx Phase 3 failure: GTX-102 shows no benefit for Angelman syndrome](https://medichelpline.com/clinical-feed/stat-news-0-stat-ultragenyx-drug-to-treat-angelman-syndrome-a-rare-disease-fails-late-stage.md)
- [Novartis scores multiple sclerosis outcome with BTK inhibitor](https://medichelpline.com/clinical-feed/stat-news-1-stat-novartis-gets-multiple-sclerosis-win-with-btk-inhibitor.md)
- [Reduced added sugar in the first 1,000 days tied to lower Alzheimer’s and dementia risk](https://medichelpline.com/clinical-feed/medical-news-today-0-cutting-added-sugar-before-age-2-linked-to-lower-dementia-depression-risk-in.md)
- [Time-restricted eating tied to improved cognitive performance in small pilot study](https://medichelpline.com/clinical-feed/medical-news-today-0-time-restricted-eating-linked-to-better-cognitive-function-in-pilot-study.md)

## Navigation
- [← Back to Neurology Feed](https://medichelpline.com/clinical-feed/neurology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.